Tango Therapeutics Inc. (TNGX)
NASDAQ · Healthcare
Tango Therapeutics Inc. Operating Income 2020–2025
Tango Therapeutics Inc. annual/quarterly operating income history and growth rate from 2020 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Tango Therapeutics Inc. operating income for the quarter ending March 31, 2026 was -48.8 M, a 14.67% increase year-over-year.
- Tango Therapeutics Inc. operating income for the twelve months ending March 31, 2026 was -118.2 M, a 9.30% decrease year-over-year.
- Tango Therapeutics Inc. annual operating income for 2025 was -111.3 M, a 23.56% decrease from 2024.
- Tango Therapeutics Inc. annual operating income for 2024 was -145.6 M, a 27.52% increase from 2023.
- Tango Therapeutics Inc. annual operating income for 2023 was -114.2 M, a 2.79% increase from 2022.
- Tango Therapeutics Inc. annual operating income for 2022 was -111.1 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Tango Therapeutics Inc. Operating Income — FAQ
Tango Therapeutics Inc. (TNGX) operating income over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
What is Tango Therapeutics Inc.'s operating income?
Tango Therapeutics Inc. (TNGX) reported operating income of -$111M for fiscal 2025.
Where can I see TNGX's operating income history?
The chart and table above show Tango Therapeutics Inc.'s operating income by year and by quarter, including the growth rate.